Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactobacillus reuteri Y7
- Development stage
- Preclinical
- Lead developer
- Taipei Medical University
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus reuteri Y7 is a human-derived probiotic strain originally isolated from healthy breast milk and deposited under the ID BCRC 911162. Developed and researched primarily by Taipei Medical University, this strain is being investigated for its therapeutic potential in neurodegenerative and inflammatory disorders. In preclinical studies, oral administration of Lactobacillus reuteri Y7 has demonstrated significant neuroprotective, antioxidant, and anti-inflammatory properties. In animal models of Parkinson's disease, Y7 supplementation attenuates both motor and non-motor impairments, reduces dopaminergic neurodegeneration, and improves mitochondrial function. Additionally, in murine models of chronic blue light exposure, Y7 protects against retinal degeneration by modulating the gut-retina axis, preserving retinal morphology, and suppressing pro-inflammatory pathways.
- Other names
- BCRC 911162BCRC911162BCRC-911162L. reuteri Y7Y7Y-7Y 7lactobacillus reuteri Y7
Beyond the preview
Go deeper on Lactobacillus reuteri Y7.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lactobacillus reuteri Y7.